GlucoTrack Secures New Patents for Blood Glucose Monitoring Technology
GlucoTrack Inc. has seen its stock price drop by 9.69%, hitting a 52-week low amid broader market declines, with the Nasdaq-100 down 0.63% and the S&P 500 down 0.33%.
The company recently secured three new patents from the U.S. Patent and Trademark Office for its continuous blood glucose monitoring technology, which enhances its intellectual property portfolio and positions it for future commercialization. This development is expected to generate new revenue streams and strengthen GlucoTrack's market position, despite the current stock decline.
The acquisition of these patents is a significant step for GlucoTrack, as it moves closer to bringing its implantable monitoring system to market, which could positively impact its long-term growth and investor confidence.
Trade with 70% Backtested Accuracy
Analyst Views on GCTK
About GCTK
About the author

- Patent Approval: Glucotrack has secured three new patents from the U.S. Patent and Trademark Office, numbered US 12,453,494, US 12,458,257, and US 12,458,258, which cover critical technologies for its implantable continuous blood glucose monitoring platform, thereby enhancing the company's intellectual property portfolio.
- Technology Protection: The new patents protect innovations in sensor chemistry, intravascular lead design, and low-power electronics, all of which are integral to Glucotrack's implantable system, ensuring a competitive edge in the market.
- Positive Market Reaction: Following the patent announcement, Glucotrack's stock rose over 12% in Thursday's premarket trading, reflecting investor optimism regarding the company's future commercialization prospects, which could drive an increase in market value.
- Accelerated Commercialization: With the acquisition of these new patents, Glucotrack's long-term implantable monitoring system is closer to commercialization, expected to generate new revenue streams and strengthen its position in the medical device market.

- Financing Agreement Reached: Glucotrack has entered into a securities purchase agreement with a single institutional investor to sell 1,033,591 shares of common stock and warrants for 2,067,182 shares, expected to generate approximately $4 million, enhancing the company's liquidity to support operations.
- Warrant Details: The warrants have an exercise price of $3.87 per share and will not be exercisable until shareholder approval is obtained, which is expected to provide flexibility in the company's future capital structure and support its long-term growth strategy.
- Planned Use of Funds: The company intends to use the net proceeds from this offering for working capital and general corporate purposes, aiming to enhance its R&D capabilities and market promotion to further drive the commercialization of its diabetes monitoring technology.
- Compliance Statement: The securities transaction relies on an exemption under Section 4(a)(2) of the Securities Act of 1933, with unregistered securities restricted from sale in the U.S., ensuring the company operates within compliance frameworks during its fundraising activities.

U.S. Stock Futures: U.S. stock futures rose this morning, with the Dow futures increasing by over 50 points, while several stocks, including New Mountain Finance Corporation, experienced significant declines in pre-market trading.
Stock Movements: New Mountain Finance shares fell 4.4% after a downgrade by B of A Securities, while other stocks like Kindly MD and aTyr Pharma saw sharp declines of 37.1% and 19.7%, respectively, following previous gains.

Check-Cap Ltd Merger Announcement: Check-Cap Ltd's shares surged 183% in pre-market trading following the announcement of a definitive merger agreement with MBody AI, which Chairman David Lontini described as a strategic move into a high-growth industry.
Other Notable Pre-Market Movements: Several stocks experienced significant pre-market trading changes, including Helius Medical Technologies (up 163.2%), InnSuites Hospitality Trust (up 118%), and AtlasClear Holdings (up 69.5%), while ECD Automotive Design and Sidus Space saw declines of 27.2% and 26.3%, respectively.
U.S. Stock Market Performance: The Dow Jones index fell over 200 points, down 0.44%, while the NASDAQ rose 0.41% and the S&P 500 gained 0.01%. Utilities stocks increased by 0.5%, but materials stocks dropped by 0.6%.
Consumer Sentiment Decline: The University of Michigan consumer sentiment index decreased to 55.4 in September from 58 in August, falling short of market expectations.
Notable Stock Movements: Allied Gaming & Entertainment shares surged 113% after announcing a Bitcoin and Ethereum investment, while GlucoTrack, Inc. rose 80% following a stock purchase agreement. Conversely, Next Technology Holding Inc. shares plummeted 54% due to a reverse stock split.
Global Market Trends: European shares were mixed, with the eurozone's STOXX 600 slightly up, while Asian markets mostly closed higher, led by Japan's Nikkei 225 gaining 0.89%.
U.S. Stock Market Performance: U.S. stocks showed mixed results, with the Dow Jones falling 0.16%, while the NASDAQ rose 0.08%. Utilities stocks increased by 0.3%, but materials stocks dropped by 0.4%.
Adobe's Strong Earnings: Adobe Inc. reported better-than-expected third-quarter earnings of $5.31 per share and raised its fiscal 2025 outlook, with quarterly revenue reaching $5.99 billion.
Notable Stock Movements: Allied Gaming & Entertainment shares surged 106% after announcing investments in Bitcoin and Ethereum, while Next Technology Holding shares plummeted 55% following a reverse stock split.
Global Market Trends: European shares were mixed, with the eurozone's STOXX 600 rising 0.2%, while Asian markets mostly closed higher, led by Japan's Nikkei 225 gaining 0.89%.







